Akatinib/Acalatinib: New developments in medical insurance prices and drug purchasing

Acalabrutinib/Acalabrutinib, this innovative drug, is widely used to treat multiple types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Acotinib has demonstrated significant therapeutic effects in both relapsed and first-treatment patients.

As a second-generation Bruton's tyrosine kinase inhibitor, acotinib effectively blocksBruton's tyrosine kinase, an enzyme critical for B cell survival and growth. By inhibiting the activity of this enzyme, acotinib slows the accumulation of cancerous B cells in CLL, thereby halting the progression of the cancer. Although some patients may experience side effects such as headache, fatigue, or cytopenias, acotinib has become a ray of hope for many patients since it was approved for medical use in the United States in 2017 and in the European Union in November 2020.

What is gratifying is that the original drug of acotinib has been launched in the domestic market and has been included in the medical insurance system, providing a wider range of medication options for patients. Common pharmaceutical specifications of 100mg, 8 pills and 7 plates, although the market price per box is as high as more than 40,000 yuan, the actual burden on patients will be reduced thanks to medical insurance reimbursement. Of course, due to differences in reimbursement ratios between regions, the final amount paid by the patient will be different. For specific details, it is recommended to consult the local medical insurance bureau or relevant medical institutions.

Currently, generic drugs similar to acotinib are on the market overseas, and their active ingredients are almost the same as the original drug. For example, a well-known pharmaceutical company in Laos launched a 100mg*60-tablet medicine with a market price of only more than 3,000 yuan, providing patients with a more economical choice. Of course, this price may be adjusted based on exchange rate fluctuations.